NHS v Servier: unlawful means tort claim fails, but the long-running saga continues
The latest episode in the long-running dispute between the NHS and French pharmaceutical company Servier has been marked by a UK Supreme Court judgment of July 2, 2021 on Servier’s application to strike out the NHS’s unlawful means tort claim.
A new drug pricing system reform proposal in Japan
A Japanese think tank is recommending an overhaul of Japan’s drug pricing system. Takanori Abe of Abe and Partners reports.
UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver
In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
UK experimental use exemptions: Part 3—the expanded exemption
In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.
Growing pains
Is the ‘essentially derived varieties’ concept protecting plant varieties or chilling innovation, ask Joel Smith and Burkhart Goebel of Hogan Lovells.
UK experimental use exemptions: Part 2—the Bolar exemption
In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.
UK experimental use exemptions: part 1—the original
In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement
Conference preview: ACI breaks down Section 337 at the 13th Annual Practitioners’ Think Tank
Making sense of the newest Section 337 developments will be a key focus of The American Conference Institute’s 13th Annual Practitioners’ Think Tank on ITC Litigation and Enforcement.
Navigating patent eligibility in digital healthcare
Patent applicants with digital health inventions need to remember that being useful and novel may not be enough, warn Linda Thayer, Aaron Capron and Sneha Nyshadham of Finnegan, Henderson, Farabow, Garrett & Dunner.
The curious case of Wuhan’s Institute of Virology and remdesivir
Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.
